A menopause conversation about weight should have room for much more than the scales. Muscle, bone health, nourishment and heart and metabolic health all matter to the life someone wants to live.
That is what interests me about this Spanish Menopause Society statement on incretin medicines, a group of hormone-based metabolic treatments. It brings research and expert judgement together for women in perimenopause and after menopause.
Guidance, rather than a new trial
The authors say direct menopause-specific evidence is limited and mostly comes from observing people rather than assigning treatments. This is not a new randomised trial or an Australian prescribing rule.
It discusses an association between hormone therapy and greater weight loss with semaglutide, the active ingredient in Ozempic. That connection is not a reason to start hormones solely to increase weight loss.
For me, the useful message is to ask about the whole person. Menopause care still needs an individual assessment, with a clear understanding of what each treatment is intended to help.